Search

Displaying results 2891 - 2900 of 5451 in total
  1. Drug

    Cocarboxylase

    go.drugbank.com/drugs/DB01987
    ApprovedInvestigational

    It is a required intermediate in the pyruvate dehydrogenase complex and the ketoglutarate dehydrogenase complex.

  2. Drug

    Carindacillin

    go.drugbank.com/drugs/DB09319
    ApprovedWithdrawn

    It is no longer marketed in the United States.

  3. Drug

    KT-A261

    go.drugbank.com/drugs/DB19317
    Experimental

    KT-A261 is an adeno-associated viral vector serotype 2 (AAV2) encoded to express adalimumab. It is being investigated for the treatment of noninfectious uveitis.

  4. Drug

    Retapamulin

    go.drugbank.com/drugs/DB01256
    Approved

    It was approved by the FDA in April 2007.

  5. Drug

    Oxogluric acid

    go.drugbank.com/drugs/DB08845
    InvestigationalNutraceutical

    Oxogluric acid is sold as a dietary supplement to athletes to improve their performance by helping to remove excess ammonia, but it is not officially approved for this indication and only experimental … the Krebs cycle as an intermediate, is involved in transamination reactions during the metabolism of amino acids, forms glutamic acid by combining with ammonia, and reduces nitrogen by combining with it

  6. Drug

    Polysorbate 20

    go.drugbank.com/drugs/DB11178
    Approved

    It is composed of 20 repeated units of polyethylene glycol via ethoxylation. … It is also an excipient that stabilizes emulsions and suspensions in pharmaceutical products and lubricant in ophthalmic solutions.

  7. Drug

    Metandienone

    go.drugbank.com/drugs/DB13586
    ApprovedWithdrawn

    It was introduced to the market in the 1960s but later discontinued and withdrawn from the market. … Although it is prohibited in and outside competition by the World Anti-Doping Agency, metandienone continues to be marketed and misused as a performance-enhancing drug in sports.

  8. Drug

    Ixabepilone

    go.drugbank.com/drugs/DB04845
    ApprovedInvestigational

    It has a lactone–lactam modification that minimizes susceptibility to esterase degradation. … It was FDA approved on October 16, 2007, for the treatment of unresponsive aggressive metastatic or locally advanced breast cancer.

    Products: IXEMPRA FOR INJECTION 15 MG, IXEMPRA (FOR INJECTION 15 MG)
  9. Drug

    Fecal microbiota

    go.drugbank.com/drugs/DB17743
    ApprovedInvestigational

    Human fecal matter is then tested for a panel of transmissible pathogens and processed with methods aimed at preserving bacterial viability.

  10. Drug

    Scopolamine

    go.drugbank.com/drugs/DB00747
    ApprovedInvestigational

    [A228423, A228758] As a result of its anticholinergic effects, scopolamine is being investigated for diverse therapeutic applications; currently, it is approved for the prevention of nausea and vomiting